Article Text

Download PDFPDF

601 An imbalance between regulatory and pro-inflammatory T cell subsets distinguishes symptomatic from asymptomatic individuals with anti-nuclear antibodies
  1. Emma Vanlieshout1,
  2. Rashi Gupta1,
  3. Kieran Manion1,
  4. Dennisse Bonilla1,
  5. Michael Kim1,
  6. Sindhu R Johnson2,
  7. Linda T Hiraki3,
  8. Zareen Ahmad2,
  9. Zahi Touma1,4,
  10. Arthur Bookman5 and
  11. Joan E Wither1,5
  1. 1Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Canada
  2. 2Toronto Scleroderma Program, Division of Rheumatology, Toronto Western and Mount Sinai Hospitals, Toronto, Canada
  3. 3Division of Rheumatology, The Hospital for Sick Children, Toronto, Canada
  4. 4University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Schroeder Arthritis Institute, University Health Network, Toronto, Canada
  5. 5Division of Rheumatology, Schroeder Arthritis Institute, University Health Network, Toronto, Canada


Background ANA+systemic autoimmune rheumatic diseases (SARD), including SLE, have a prolonged pre-clinical phase during which ANAs can be detected in the absence of clinical symptoms. ANAs are also seen in healthy individuals, most of whom will not progress to SARD. The immunological changes that promote development of clinical symptoms in SARD and conversely maintain benign autoimmunity in asymptomatic ANA+ individuals (ANA+NS) remain largely unexplored. To address this question, peripheral blood immune populations were examined in ANA+ individuals, with and without SARD.

Methods ANA+ (IF ≥ 1:160) subjects were classified as ANA+NS (n=61, no SARD criteria), undifferentiated connective tissue disease (UCTD, n=54, SARD criteria but lacking sufficient criteria for a diagnosis), or early SARD (SLE, n=10, SjD, n=7, SSc, n=5). All SARD patients were within 2 years of diagnosis and not taking Disease Modifying Anti-Rheumatic Drugs (hydroxychloroquine allowed) or prednisone. ANAHC (n=21) were also recruited. Peripheral blood mononuclear cells were isolated and stained with fluorochrome labeled antibodies to identify immune cell populations via flow cytometry. Plasma TGF-ß1 levels were measured by ELISA.

Results We previously showed that ANA+NS and UCTD patients have increased B cell activation and expansion of T follicular helper (Tfh) cells, similar to that seen in SARD. Here we show that T peripheral helper (Tph) cells are also increased in ANA+NS and demonstrate further progressive increases in UCTD and SARD, resulting in a significant increase in SARD relative to ANA+NS. In ANA+NS and UCTD the majority of Tfh and Tph cells had a Th2 phenotype, leading to increased proportions of Tfh2 and Tph2 cells, as compared to ANA-HC. In addition to these increases, SARD patients had significant elevations of Tph17 cells. Increases in Extrafollicular and Type 1 Regulatory T cells were also seen in ANA+NS and UCTD, relative to ANA-HC, with SARD patients demonstrating a trend to normalization of these populations. Similar changes were seen in the levels of TGF-ß1. ANA+ individuals who demonstrated symptomatic progression within the subsequent 2 years (n=12) had significantly increased levels of activated class-switched and double negative memory B cells, plasmablasts, plasma cells, and Tph cells at baseline visit, as compared to those who remained stable over the same period of time.

Conclusion Collectively, our findings suggest active immunoregulation prevents clinical autoimmunity in ANA+NS, and that this is impaired in patients with SARD, resulting in an imbalance between Tregs and pro-inflammatory T helper cell subsets.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.